HIV-1 Subtype-specific Drug Resistance in Patients Failing Dolutegravir (DTG) Based Regimen
This is a prospective observational study enrolling People Living with HIV (PLHIV) who are on a Dolutegravir-based AntiRetroviral Treatment (ART) regimen and experiencing virologic failure. Virologic failure is defined as two consecutive viral load measurements of >1000 copies/mL of blood. The main aim of the study is to identify the drug-resistance mutations in the viral genome that are associated with this failure.

To achieve this goal, patients fulfilling the eligibility criteria will be invited for a single study visit for the collection of blood. The extracted HIV virus will be sequenced through whole genome sequencing methods to identify the drug-resistance mutations. The study is conducted in 15-20 countries within six regions of the IeDEA cohort (International epidemiology Databases to Evaluate AIDS).
- EligibilityCriteria: Inclusion Criteria:  Adults aged 18 years or older and adolescents (10-17 years) On any DTG-based ART regimen Who develop virologic failure (VF) defined as a VL >1000 copies/mL (single or confirmed measurement), and have signed the informed consent.  Exclusion Criteria:  No Informed Consent - HealthyVolunteers: No - Gender: All - MinimumAge: 10 Years - StdAgeList: Child, Adult, Older Adult - StudyPopulation: Patients routinely treated at the local HIV care clinics. - SamplingMethod: Probability Sample